Ibalizumab is a humanized monoclonal antibody and a long-acting antiretroviral agent used in combination with other antiretroviral medicines for the treatment of multidrug-resistant HIV-1 infection in appropriately selected patients.
Unlike conventional antiretroviral drugs that directly inhibit viral enzymes, Ibalizumab binds to the CD4 receptor on host T cells and interferes with the entry of HIV-1 into CD4+ cells. This distinctive mechanism makes it an important therapeutic option for patients with limited treatment options because of multidrug-resistant HIV-1.
Ibalizumab is a complex biological pharmaceutical active ingredient produced using recombinant biotechnology rather than conventional small-molecule chemical synthesis. Manufacturing requires controlled cell-culture processes, downstream purification and extensive characterization of the monoclonal antibody.
Quality control for Ibalizumab focuses on identity, purity, potency, aggregation, charge variants, glycosylation, protein concentration, host-cell proteins, residual DNA and other process-related impurities.
CAS Number: 674782-97-3
Molecular Type: Humanized Monoclonal Antibody
Drug Class: Antiretroviral Agent
Pharmacological Class: CD4-Directed Monoclonal Antibody
Therapeutic Class: HIV Antiretroviral
Therapeutic Area: Infectious Diseases
Target: CD4 Receptor
Primary Application: Multidrug-Resistant HIV-1 Infection
Ibalizumab binds to a specific epitope on the CD4 receptor expressed on T lymphocytes.
Its binding interferes with the conformational changes and interactions required for HIV-1 entry into CD4+ cells. Importantly, it does not prevent normal CD4 receptor interaction with major histocompatibility complex molecules to the same extent as antibodies that target other CD4 regions.
Through this post-attachment entry inhibition, Ibalizumab prevents HIV-1 from efficiently entering susceptible CD4+ T cells.
Ibalizumab is used in combination with other antiretroviral agents for patients with:
The exact use and eligibility depend on approved regulatory labeling and clinical guidelines.
Ibalizumab represents a different therapeutic approach from traditional antiretroviral agents because it targets the host CD4 receptor rather than directly targeting an HIV viral enzyme.
This mechanism provides an additional treatment option for appropriately selected patients whose HIV-1 has developed resistance to multiple conventional antiretroviral drug classes.
As a monoclonal antibody, Ibalizumab requires a sophisticated biological manufacturing platform. Important manufacturing stages may include:
The manufacturing process must be appropriately validated and controlled to maintain product consistency.
Ibalizumab quality evaluation may include:
For biological APIs, specifications are generally product-specific and process-specific, rather than being represented by a simple small-molecule assay percentage.
Ibalizumab drug substance and finished pharmaceutical products require controlled temperature and handling conditions appropriate to the validated stability profile of the biological product. Exposure to excessive heat, freezing, agitation or unsuitable storage conditions can adversely affect monoclonal antibody quality.
Ibalizumab is relevant to research involving HIV-1 entry inhibition, CD4-targeted monoclonal antibodies, multidrug-resistant HIV and biologic antiretroviral therapies.
Ibalizumab is a humanized monoclonal antibody targeting the CD4 receptor with CAS Number 674782-97-3. It provides a distinctive post-attachment HIV-1 entry-inhibition mechanism and is used with other antiretroviral agents for appropriately selected patients with multidrug-resistant HIV-1 and limited treatment options.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| pH (1% Solution) | 4.0 – 7.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 1.0% |